Generic Yaz: Still Dangerous

            Although many people are familiar at this point with Yaz side effects associated with Yaz birth control due to the intense media coverage surrounding risks associated with the popular birth control, not everyone knows the full story. Blood clots and other side effects associated with Yaz usage can be seen in other forms of the drug, such as generics. A new form of generic Yaz has been approved by the Food and Drug Administration for release into the United States pharmaceuticals market, called Loryna. It is manufactured by Sandoz.

            This is the second form of generic Yaz available in the United States – the first was called Gianvi, introduced to the market in June 2010. Although there are still hundreds of Yaz lawsuits in state and federal courts across the country, this new product might increase the number of side effects being experienced by patients. Yaz and similar products remain popular forms of birth control for women, despite the risks that have been outlined in the media.

            Drospirenone and ethinyl estradiol are the active ingredients in both Yaz and the newer Loryna, meaning that the side effects of these products will likely mimic one another. Young women who have taken this birth control have experienced Yaz gallbladder disease, pulmonary embolism, and deep vein thrombosis. Many Yaz side effects are related to blood clotting.

            Many of the nearly 8,000 Yaz lawsuits have to do with generic forms of the product, which carry the same complications as the original product. Safyral and Beyaz are also similar products that are involved in some of the Yaz litigation, but also include metafolin, which helps reduce birth defects in women who get pregnant shortly after ceasing their birth control treatment.

            It is still to be seen what kind of side effects will manifest with Loryna, but they are likely to be almost identical to complications related to Yaz.

Meta